Wedbush Analysts Boost Earnings Estimates for BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Equities research analysts at Wedbush boosted their Q3 2025 EPS estimates for BioCryst Pharmaceuticals in a research report issued to clients and investors on Monday, May 5th. Wedbush analyst L. Chico now forecasts that the biotechnology company will post earnings of $0.04 per share for the quarter, up from their prior estimate of $0.02. Wedbush currently has a "Outperform" rating and a $15.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' Q4 2025 earnings at $0.07 EPS.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The business's quarterly revenue was up 40.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.28 earnings per share.

Other equities research analysts have also recently issued research reports about the company. Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research note on Monday, January 13th. Cantor Fitzgerald assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price for the company. Royal Bank of Canada restated an "outperform" rating and issued a $13.00 price target (up previously from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Needham & Company LLC lifted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Price Performance

NASDAQ BCRX traded up $0.06 during trading hours on Wednesday, reaching $9.98. The company's stock had a trading volume of 7,606,302 shares, compared to its average volume of 2,991,433. The firm has a fifty day simple moving average of $7.87 and a 200-day simple moving average of $7.89. BioCryst Pharmaceuticals has a 52 week low of $5.23 and a 52 week high of $11.11. The stock has a market cap of $2.09 billion, a P/E ratio of -16.36 and a beta of 1.08.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Headlands Technologies LLC purchased a new position in shares of BioCryst Pharmaceuticals in the first quarter valued at about $32,000. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $33,000. GAMMA Investing LLC increased its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock valued at $44,000 after purchasing an additional 5,449 shares during the period. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $46,000. Finally, R Squared Ltd purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.